Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 41Stomach Neoplasms 2Neoplasm Metastasis 2HER2-positive Breast Cancer 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1Solid Tumors 1Recurrence 1Patient Preference 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Inflammatory Breast Neoplasms 1HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy 1HER2-Positive Primary Breast Cancer 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Cancer Metastatic 1Brain Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1Adenocarcinoma Of Esophagus 1

Interventions

trastuzumab deruxtecan 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER2-Positive Primary Breast Cancer × Ado-Trastuzumab Emtansine × Clear all
NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡